Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis

Cellular and Molecular Life Sciences

Volumn 61, Issue 3, 2004, Pages 301-325

  Silverman, G A ^a   Whisstock, J C ^b   Askew, D J ^a   Pak, S C ^a   Luke, C J ^a   Cataltepe, S ^a   Irving, J A ^b   Bird, P I ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Apoptosis; Cell death; Clade B serpin; Cysteine proteinase; Evolution; Innate immunity; Intracellular serpin; ov serpin; Proteinase inhibitor; Serine proteinase; Serpin; Tumor invasion

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 ANTIPLASMIN; ANGIOTENSINOGEN; ANTITHROMBIN III; CHYMOTRYPSIN INHIBITOR; COMPLEMENT COMPONENT C1S INHIBITOR; CYSTEINE PROTEINASE; HEAT SHOCK PROTEIN 47; HEPARIN COFACTOR; LEUKOCYTE ELASTASE INHIBITOR; NEUROSERPIN; OVALBUMIN; PANCPIN; PAPAIN; PDZ PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEASE NEXIN I; PROTEINASE INHIBITOR; SERINE; SERINE PROTEINASE INHIBITOR; SIGNAL PEPTIDE; SQUAMOUS CELL CARCINOMA ANTIGEN 1; THYROXINE BINDING GLOBULIN; TRANSCORTIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; UTERUS MILK PROTEIN;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; BACTERIUM; BLOOD CLOT LYSIS; BLOOD CLOTTING; CELL PROTECTION; CELLULAR DISTRIBUTION; CIRCULATION; CLADISTICS; COMPLEMENT SYSTEM; CONFORMATIONAL TRANSITION; COVALENT BOND; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DISPERSION; EUKARYOTE; GENE EXPRESSION; GENE STRUCTURE; GENETIC CODE; GENETIC ORGANIZATION; HUMAN; HUMAN GENOME; HUMAN VERSUS ANIMAL COMPARISON; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SPECIES COMPARISON; TISSUE DISTRIBUTION; VIRUS;

AMINO ACID SEQUENCE; ANIMALS; EVOLUTION, MOLECULAR; GENE EXPRESSION REGULATION; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; SERINE PROTEINASE INHIBITORS; SERPINS;

ANIMALIA; ARCHAEA; BACTERIA (MICROORGANISMS); EUKARYOTA;

EID: 1242298756     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-003-3240-3     Document Type: Review

References (166)

1. Gettins P. G. (2002) Serpin structure, mechanism and function. Chem. Rev. 102: 4751-4803
2. Silverman G. A., Bird P. I., Carrell R. W., Coughlin P. B., Gettins P. G., Irving J. I. et al. (2001) The serpins are an expanding superfamily of structurally similar but funtionally diverse proteins: evolution, mechanism of inhibition, novel functions and a revised nomenclature. J. Biol. Chem. 276: 33293-33296
3. Remold-O'Donnell E. (1993) The ovalbumin family of serpin proteins, FEBS Lett. 315: 105-108
4. Irving J. A., Pike R. N., Lesk A. M. and Whisstock J. C. (2000) Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res. 10: 1845-1864
5. Irving J. A., Steenbakkers P. J., Lesk A. M., Op den Camp H. J., Pike R. N. and Whisstock J. C. (2002) Serpins in prokaryotes. Mol. Biol. Evol. 19: 1881-1890
6. Ragg H., Lokot T., Kamp P. B., Atchley W. R. and Dress A. (2001) Vertebrate serpins: construction of a conflict-free phylogeny by combining exon-intron and diagnostic site analyses. Mol. Biol. Evol. 18: 577-584
7. Scott F. L., Eyre H. J., Lioumi M., Ragoussis J., Irving J. A., Sutherland G. A. et al. (1999) Human ovalbumin serpin evolution: phylogenic analysis, gene organization, and identification of new PI8-related genes suggest that two interchromosomal and several intrachromosomal duplications generated the gene clusters at 18q21-q23 and 6p25. Genomics 62: 490-499
8. Kumar S. and Hedges S. B. (1998) A molecular timescale for vertebrate evolution. Nature 392: 917-920.
9. Askew Y. S., Pak S. C., Luke C. J., Askew D. J., Cataltepe S., Mills D. R. et al. (2001) SERPINB12 is a novel member of the human ov-serpin family that is widely expressed and inhibits trypsin-like serine proteinases. J. Biol. Chem. 276: 49320-49330
10. Bartuski A. J., Kamachi Y., Schick C., Overhauser J. and Silverman G. A. (1997) Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics 43: 321-328
11. Eyre H. J., Sun J., Sutherland G. R. and Bird P. (1996) Chromosomal mapping of the gene (PI9) encoding the intracellular serpin proteinase inhibitor 9 to 6p25 by fluorescence in situ hybridization. Genomics 37: 406-408
12. Evans E., Cooley J. and Remold-O'Donnell E. (1995) Characterization and chromosomal localization of ELANH2, the gene encoding human monocyte/neutrophil elastase inhibitor. Genomics 28: 235-240
13. Loebermann H., Tokuoka R., Deisenhofer J. and Huber R. (1984) Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177: 531-557
14. Stein P. E., Leslie A. G., Finch J. T., Turnell W. G., McLaughlin P. J. and Carrell R. W. (1990) Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 347: 99-102
15. Wright H. T., Qian H. X. and Huber R. (1990) Crystal structure of plakalbumin, a proteolytically nicked form of ovalbumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor. J. Mol. Biol. 213: 513-528
16. Wei A., Rubin H., Cooperman B. S. and Christianson D. W. (1994) Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nature Struct. Biol. 1: 251-257
17. Carrell R. W. and Owen M. C. (1985) Plakalbumin, alpha 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 317: 730-2
18. Stein P. E., Tewkesbury D. A. and Carrell R. W. (1989) Ovalbumin and angiotensinogen lack serpin S-R conformational change. Biochem J. 262: 103-7
19. Huntington J. A., Read R. J. and Carrell R. W. (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407: 923-926
20. Schechter I. and Berger A. (1967) On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27: 157-162
21. Yamasaki M., Arii Y., Mikami B. and Hirose M. (2002) Loop-inserted and thermostabilized structure of P1-P1′ cleaved ovalbumin mutant R339T. J. Mol. Biol. 315: 113-120
22. Sugimoto Y., Sanuki S., Ohsako S., Higashimoto Y., Kondo M., Kurawaki J. et al. (1999) Ovalbumin in developing chicken eggs migrates from egg white to embryonic organs while changing its conformation and thermal stability. J. Biol. Chem. 274: 11030-11037
23. Lukacs C. M., Zhong J. Q., Plotnick M. I., Rubin H., Cooperman B. S. and Christianson D. W. (1996) Arginine substitutions in the hinge region of antichymotrypsin affect serpin beta-sheet rearrangement. Nat. Struct. Biol. 3: 888-893
24. Baumann U., Bode W., Huber R., Travis J. and Potempa J. (1992) Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95 A resolution. J. Mol. Biol. 226: 1207-1218
25. Harrop S. J., Jankova L., Coles M., Jardine D., Whittaker J. S., Gould A. R. et al. (1999) The crystal structure of plasminogen activator inhibitor 2 at 2.0 A resolution: implications for serpin function. Structure Fold Des. 7: 43-54
26. Jankova L., Harrop S. J., Saunders D. N.,Andrews J. L., Bertram K. C., Gould A. R. et al. (2001) Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop. J. Biol. Chem. 276: 43374-43382
27. Dickinson J. L., Norris B. J., Jensen P. H. and Antalis T. M. (1998) The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ. 5: 163-171
28. Whisstock J. C., Skinner R., Carrell R. W. and Lesk A. M. (2000) Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin. J. Mol. Biol. 296: 685-699
29. Berman H. M., Westbrook J., Feng Z., Gilliland G., Bhat T. N., Weissig H. et al. (2000) The Protein Data Bank. Nucleic Acids Res. 28: 235-242
30. Remold-O'Donnell E. (1985) A fast-acting elastase inhibitor in human monocytes. J. Exp. Med. 162: 2142-55
31. Remold-O'Donnell E., Chin J. and Alberts M. (1992) Sequence and molecular characterization of human monocyte/neutrophil elastase inhibitor. Proc. Natl. Acad. Sci. USA 89: 5635-5639
32. Dubin A., Travis J., Enghild J. J. and Potempa J. (1992) Equine leukocyte elastase inhibitor. Primary structure and identification as a thymosin-binding protein. J. Biol. Chem. 267: 6576-6583
33. Cooley J., Takayama T. K., Shapiro S. D., Schechter N. M. and Remold-O'Donnell E. (2001) The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry 40: 15762-15770
34. Rees D. D., Rogers R. A., Cooley J., Mandle R. J., Kenney D. M. and Remold-O'Donnell E. (1999) Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am. J. Respir. Cell. Mol. Biol. 20: 69-78
35. Packard B. Z., Lee S. S., Remold-O'Donnell E. and Komoriya A. (1995) A serpin from human tumor cells with direct lymphoid immunomodulatory activity: mitogenic stimulation of human tumor-infiltrating lymphocytes. Biochim. Biophys. Acta 1269: 41-50
36. Torriglia A., Perani P., Brossas J. Y., Chaudun E., Treton J., Courtois Y. et al. (1998) L-DNase II, a molecule that links proteases and endonucleases in apoptosis, derives from the ubiquitous serpin leukocyte elastase inhibitor [published erratum appears in Mol Cell Biol 1998 Aug;18(8):4947]. Mol. Cell. Biol. 18: 3612-3619
37. Belmokhtar C. A., Torriglia A., Counis M. F., Courtois Y., Jacquemin-Sablon A. and Segal-Bendirdjian E. (2000) Nuclear translocation of a leukocyte elastase Inhibitor/Elastase complex during staurosporine-induced apoptosis: role in the generation of nuclear L-DNase II activity. Exp. Cell. Res. 254: 99-109.
38. Altairac S., Zeggai S., Perani P., Courtois Y. and Torriglia A. (2003) Apoptosis induced by Na(+)/H(+) antiport inhibition activates the LEI/L-DNase II pathway. Cell. Death Differ. 10: 548-557
39. Bachmann F. (1995) The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb. Haemost. 74: 172-179
40. Kruithof E. K. O., Baker M. S. and Bunn C. L. (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86: 4007-4024
41. Ellis V., Wun T. C., Behrendt N., Ronne E. and Dano K. (1990) Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 265: 9904-9908
42. Pollanen J., Vaheri A., Tapiovaara H., Riley E., Bertram K., Woodrow G. et al. (1990) Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 87: 2230-2234
43. Kruithof E. K., Vassalli J. D., Schleuning W. D., Mattaliano R. J. and Bachmann F. (1986) Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J. Biol. Chem. 261: 11207-11213
44. Ye R. D., Wun T. C. and Sadler J. E. (1988) Mammalian protein secretion without signal peptide removal. Biosynthesis of plasminogen activator inhibitor-2 in U-937 cells. J. Biol. Chem. 263: 4869-4875
45. Jensen P. J., Wu Q., Janowitz P., Ando Y. and Schechter N. M. (1995) Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp. Cell. Res. 217: 65-71
46. Jensen P. H., Schuler E., Woodrow G., Richardson M., Goss N., Hojrup P. et al. (1994) A unique interhelical insertion in plasminogen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cross-linking. J. Biol. Chem. 269: 15394-15398
47. Dougherty K. M., Pearson J. M., Yang A. Y., Westrick R. J., Baker M. S. and Ginsburg D. (1999) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc. Natl. Acad. Sci. USA 96: 686-691
48. Kumar S. and Baglioni C. (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J. Biol. Chem. 266: 20960-20964
49. Dickinson J. L., Bates E. J., Ferrante A. and Antalis T. M. (1995) Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J. Biol. Chem. 270: 27894-27904
50. Antalis T. M., La Linn M., Donnan K., Mateo L., Gardner J., Dickinson J. L. et al. (1998) The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J. Exp. Med. 187: 1799-1811
51. Foekens J. A., Buessecker F., Peters H. A., Krainick U., van Putten W. L., Look M. P. et al. (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res. 55: 1423-1427
52. Nagayama M., Sato A., Hayakawa H., Urano T., Takada Y. and Takada A. (1994) Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 73: 1398-1405
53. Hasina R., Hulett K., Bicciato S., Di Bello C., Petruzzelli G. J. and Lingen M. W. (2003) Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 63: 555-559
54. Takeuchi Y., Nakao A., Harada A., Nonami T., Fukatsu T. and Takagi H. (1993) Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am. J. Gastroenterol. 88: 1928-1933
55. Mueller B. M., Yu Y. B. and Laug W. E. (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA 92: 205-209
56. Ganesh S., Sier C. F., Griffioen G., Vloedgraven H. J., de Boer A., Welvaart K. et al. (1994) Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54: 4065-4071
57. Zhou H. M., Bolon I., Nichols A., Wohlwend A. and Vassalli J. D. (2001) Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res. 61: 970-976
58. Jensen P. H., Jensen T. G., Laug W. E., Hager H., Gliemann J. and Pepinsky B. (1996) The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain. J. Biol. Chem. 271: 26892-26899
59. Wilczynska M., Lobov S., Ohlsson P. I. and Ny T. (2003) A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization. EMBO J. 22: 1753-1761
60. Kato H. (1992) Squamous cell carcinoma antigen In: Serological Cancer Markers (S. Sell, ed.) pp. 437-451, Humana Press, Totowa, NJ
61. Ngan H. Y. S., Chan S. Y. W., Wong L. C., Choy D. T. K. and Ma H. K. (1990) Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol. Oncol. 37: 260-263
62. Duk J. M., Groenier K. H., de Bruijn H. W. A., Hollema H., ten Hoor K. A., van der Zee A. G. J. et al. (1996) Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J. Clin. Oncol. 14: 111-118
63. Lara P. C. and Cuyas J. M. (1995) The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer 76: 758-764
64. Snyderman C. H., D'Amico F., Wagner R. and Eibling D. E. (1995) A reappraisal of the squamous cell carcinoma antigen as a tumor marker in head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 121: 1294-1297
65. Maruo T., Shibata K., Kimura A., M. H. and Mochizuki M. (1985) Tumor-associated antigen, TA-4, in the monitoring of the effects of therapy for squamous cell carcinoma of the uterine cervix. Cancer 56: 302-308
66. Suminami Y., Kishi F., Sekiguchi K. and Kato H. (1991) Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem. Biophys. Res. Commun. 181: 51-58
67. Schneider S. S., Schick C., Fish K. E., Miller E., Pena J. C., Treter S. D. et al. (1995) A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc. Natl. Acad. Sci. USA 92: 3147-3151
68. Schick C., Kamachi Y., Bartuski A. J., Cataltepe S., Schechter N. M., Pemberton P. A. et al. (1997) Squamous cell carcinoma antigen 2: a novel serpin that inhibits the chymotrypsin-like proteinases cathepsin G and mast cell chymase. J. Biol. Chem. 272: 1849-1855
69. Schick C., Pemberton P. A., Shi G.-P., Kamachi Y., Cataltepe S., Bartuski A. J. et al. (1998) Cross-class inhibition of the cysteine proteinases cathepsins K, L, and S by the serpin squamous cell carcinoma antigen 1: A kinetic analysis. Biochemistry 37: 5258-5266
70. Schick C., Bromme D., Bartuski A. J., Uemura Y., Schechter N. M. and Silverman G. A. (1998) The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. Proc. Natl. Acad. Sci. USA 95: 13465-13470
71. Cataltepe S., Gornstein E. R., Schick C., Kamachi Y., Chatson K., Fries J. et al. (2000) Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult tissues and squamous cell carcinomas. J. Histochem. Cytochem. 48: 113-122
72. Komiyama T., Ray C. A., Pickup D. J., Howard A. D., Thornberry N. A., Peterson E. P. et al. (1994) Inhibition of interleukin-1β converting enzyme by the cowpox virus serpin CrmA. An example of cross-class inhibition. J. Biol. Chem. 269: 19331-19337
73. Sun J., Bird C. H., Sutton V., McDonald L., Coughlin P. B., De Jong T. A. et al. (1996) A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J. Biol. Chem. 271: 27802-27809
74. Bird C. H., Sutton V. R., Sun J., Hirst C. E., Novak A., Kumar S. et al. (1998) Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol. Cell. Biol. 18: 6387-6398
75. Suminami Y., Nagashima S., Vujanovic N. L., Hirabayashi K., Kato H. and Whiteside T. L. (2000) Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br. J. Cancer 82: 981-989
76. Suminami Y., Nagashima S., Murakami A., Nawata S., Gondo T., Hirakawa H. et al. (2001) Suppression of a squamous cell carcinoma (SCC)-related serpin, SCC antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells. Cancer Res. 61: 1776-1780.
77. Murakami A., Suminami Y., Hirakawa H., Nawata S., Numa F. and Kato H. (2001) Squamous cell carcinoma antigen suppresses radiation-induced cell death. Br. J. Cancer 84: 851-858.
78. Luke C., Schick C., Tsu C., Whisstock J. C., Irving J. A., Bromme D. et al. (2000) Simple modifications of the serpin reactive site loop convert SCCA2 into a cysteine proteinase inhibitor: a critical role for the P3′ proline in facilitating RSL cleavage. Biochemistry 39: 7081-7091.
79. McGettrick A. F., Barnes R. C. and Worrall D. M. (2001) SCCA2 inhibits TNF-mediated apoptosis in transfected HeLa cells. The reactive centre loop sequence is essential for this function and TNF-induced cathepsin G is a candidate target. Eur. J. Biochem. 268: 5868-5875
80. Zou Z., Anisowicz A., Hendrix M. J., Thor A., Neveu M., Sheng S. et al. (1994) Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529
81. Sheng S., Carey J., Seftor E. A., Dias L., Hendrix M. J. and Sager R. (1996) Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA 93: 11669-11674
82. Shi H. Y., Liang R., Templeton N. S. and Zhang M. (2002) Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model. Mol. Ther. 5: 755-761
83. Jiang N., Meng Y., Zhang S., Mensah-Osman E. and Sheng S. (2002) Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 21: 4089-4098
84. Futscher B. W., Oshiro M. M., Wozniak R. J., Holtan N., Hanigan C. L., Duan H. et al. (2002) Role for DNA methylation in the control of cell type specific maspin expression. Nat. Genet. 31: 175-179
85. Zou Z., Gao C., Nagaich A. K., Connell T., Saito S., Moul J. W. et al. (2000) p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275: 6051-6054
86. Umekita Y., Ohi Y., Sagara Y. and Yoshida H. (2002) Expression of maspin predicts poor prognosis in breast-cancer patients. Int. J. Cancer 100: 452-455
87. Maass N., Hojo T., Rosel F., Ikeda T., Jonat W. and Nagasaki K. (2001) Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin. Biochem. 34: 303-307
88. Maass N., Teffner M., Rosel F., Pawaresch R., Jonat W., Nagasaki K. et al. (2001) Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J. Pathol. 195: 321-326
89. Zou Z., Zhang W., Young D., Gleave M. G., Rennie P., Connell T. et al. (2002) Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. Clin. Cancer Res. 8: 1172-1177
90. Song S. Y., Lee S. K., Kim D. H., Son H. J., Kim H. J., Lim Y. J. et al. (2002) Expression of maspin in colon cancers: its relationship with p53 expression and microvessel density. Dig. Dis. Sci. 47: 1831-1835
91. Maass N., Hojo T., Ueding M., Luttges J., Kloppel G., Jonat W. et al. (2001) Expression of the tumor suppressor gene Maspin in human pancreatic cancers. Clin. Cancer. Res. 7: 812-817
92. Sood A. K., Fletcher M. S., Gruman L. M., Coffin J. E., Jabbari S., Khalkhali-Ellis Z. et al. (2002) The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer. Res. 8: 2924-2932
93. Heighway J., Knapp T., Boyce L., Brennand S., Field J. K., Betticher D. C. et al. (2002) Expression profiling of primary non-small cell lung cancer for target identification. Oncogene 21: 7749-7763
94. Domann F. E. and Futscher B. W. (2003) Editorial: maspin as a molecular target for cancer therapy. J. Urol. 169: 1162-1164
95. Mohsin S. K., Zhang M., Clark G. M. and Craig Allred D. (2003) Maspin expression in invasive breast cancer: association with other prognostic factors. J. Pathol. 199: 432-435
96. Sheng S., Pemberton P. A. and Sager R. (1994) Production, purification, and characterization of recombinant maspin proteins. J. Biol. Chem. 269: 30988-30993
97. Hopkins P. C. R. and Whisstock J. (1994) Function of maspin. Science 265: 1893-1894
98. Pemberton P. A., Wong D. T., Gibson H. L., Kiefer M. C., Fitzpatrick P. A., Sager R. et al. (1995) The tumor suppressor maspin does not undergo the stressed to relaxed transition or inhibit trypsin-like serine proteases. Evidence that maspin is not a protease inhibitory serpin. J. Biol. Chem. 270: 15832-15837
99. Sheng S., Truong B., Fredrickson D., Wu R., Pardee A. B. and Sager R. (1998) Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc. Natl. Acad. Sci. USA 95: 499-504
100. Bass R., Fernandez A. M. and Ellis V. (2002) Maspin inhibits cell migration in the absence of protease inhibitory activity. J. Biol. Chem 277: 46845-46848
101. Zhang M., Magit D., Botteri F., Shi H. Y., He K., Li M. et al. (1999) Maspin plays an important role in mammary gland development. Dev Biol. 215: 278-287
102. Zhang M., Volpert O., Shi Y. H. and Bouck N. (2000) Maspin is an angiogenesis inhibitor. Nat. Med. 6: 196-199
103. Zhang M. (2002) The role of maspin in tumor progression and normal development. In: Hendrix M. J. C., (ed.) pp. 96-116, Maspin, Landes Bioscience, Georgetown, TX.
104. Dokras A., Gardner L. M., Kirschmann D. A., Seftor E. A. and Hendrix M. J. (2002) The tumour suppressor gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta 23: 274-280
105. Pemberton P. A., Tipton A. R., Pavloff N., Smith J., Erickson J. R., Mouchabeck Z. M. et al. (1997) Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J. Histochem. Cytochem. 45: 1697-1706
106. Coughlin P. B., Tetaz T. and Salem H. H. (1993) Identification and purification of a novel serine proteinase inhibitor. J. Biol. Chem. 268: 9541-9547
107. Morgenstern K. A., Henzel W. J., Baker J. B., Wong S., Pastuszyn A. and Kisiel W. (1993) Isolation and characterization of an intracellular serine proteinase inhibitor from a monkey kidney epithelial cell line. J. Biol. Chem. 268: 21560-21568
108. Morgenstern K. A., Sprecher C., Holth L., Foster D., Grant F. J., Ching A. et al. (1994) Complementary DNA cloning and kinetic characterization of a novel intracellular serine proteinase inhibitor: mechanism of action with trypsin and factor Xa as model proteinases. Biochemistry 33: 3432-3441
109. Coughlin P., Sun J., Cerruti L., Salem H. H. and Bird P. (1993) Cloning and molecular characterization of a human intracellular serine proteinase inhibitor. Proc. Natl. Acad. Sci. USA 90: 9417-9421
110. Riewald M. and Schleef R. R. (1996) Human cytoplasmic antiproteinase neutralizes rapidly and efficiently chymotrypsin and trypsin-like proteases utilizing distinct reactive site residues. J. Biol. Chem. 271: 14526-14532
111. Scott F. L., Hirst C. E., Sun J., Bird C. H., Bottomley S. P. and Bird P. I. (1999) The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G. Blood 93: 2089-2097
112. Kato K., Kishi T., Kamachi T., Akisada M., Oka T., Midorikawa R. et al. (2001) Serine proteinase inhibitor 3 and murinoglobulin I are potent inhibitors of neuropsin in adult mouse brain. J. Biol. Chem. 276: 14562-14571
113. Scott F. L., Paddle-Ledinek J. E., Cerruti L., Coughlin P. B., Salem H. H. and Bird P. I. (1998) Proteinase inhibitor 6 (PI-6) expression in human skin: induction of PI-6 and a PI-6/proteinase complex during keratinocyte differentiation. Exp. Cell. Res. 245: 263-271
114. Mikolajczyk S. D., Millar L. S., Marker K. M., Rittenhouse H. G., Wolfert R. L., Marks L. S. et al. (1999) Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res. 59: 3927-3930
115. Saedi M. S., Zhu Z., Marker K., Liu R. S., Carpenter P. M., Rittenhouse H. et al. (2001) Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells. Int. J. Cancer 94: 558-563
116. Tsujimoto M., Tsuruoka N., Ishida N., Kurihara T., Iwasa F., Yamashiro K. et al. (1997) Purification, cDNA cloning, and characterization of a new serpin with megakaryocyte maturation activity, J. Biol. Chem. 272: 15373-15380
117. Miyata T., Nangaku M., Suzuki D., Inagi R., Uragami K., Sakai H. et al. (1998) A mesangium-predominant gene, megsin, is a new serpin upregulated in IgA nephropathy. J. Clin. Invest. 102: 828-836
118. Inagi R., Miyata T., Imasawa T., Nangaku M. and Kurokawa K. (2002) Mesangial cell-predominant gene, megsin. Nephrol. Dial. Transplant. 17 Suppl. 9: 32-33
119. Miyata T., Inagi R., Nangaku M., Imasawa T., Sato M., Izuhara Y. et al. (2002) Overexpression of the serpin megsin induces progressive mesangial cell proliferation and expansion. J. Clin. Invest. 109: 585-593
120. Sprecher C. A., Morgenstern K. A., Mathewes S., Dahlen J. R., Schrader S. K., Foster D. C. et al. (1995) Molecular cloning, expression, and partial characterization of two novel members of the ovalbumin family of serine proteinase inhibitors. J. Biol. Chem. 270: 29854-29861
121. Strik M. C., Bladergroen B. A., Wouters D., Kisiel W., Hooijberg J. H., Verlaan A. R. et al. (2002) Distribution of the human intracellular serpin protease inhibitor 8 in human tissues. J. Histochem. Cytochem. 50: 1443-1454
122. Ah-Kim H., Zhang X., Islam S., Sofi J. I., Glickberg Y., Malemud C. J. et al. (2000) Tumour necrosis factor alpha enhances the expression of hydroxyl lyase, cytoplasmic antiproteinase-2 and a dual specificity kinase TTK in human chondrocyte-like cells. Cytokine 12: 142-150
123. Dahlen J. R., Foster D. C. and Kisiel W. (1997) Expression, purification and inhibitory properties of human proteinase inhibitor 8. Biochemistry 36: 14874-14882
124. Dahlen J. R., Foster D. C. and Kisiel W. (1998) The inhibitory specificity of human proteinase inhibitor 8 is expanded through the use of multiple reactive site residues. Biochem. Biophys. Res. Commun. 244: 172-177
125. Dahlen J. R., Jean F., Thomas G., Foster D. C. and Kisiel W. (1998) Inhibition of soluble recombinant furin by human proteinase inhibitor 8. J. Biol. Chem. 273: 1851-1844
126. Medema J. P., Schuurhuis D. H., Rea D., van Tongeren J., de Jong J., Bres S. A. et al. (2001) Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis. Differential modulation by t helper type 1 and type 2 cells. J. Exp. Med. 194: 657-668
127. Hirst C. E., Buzza M. S., Bird C. H., Warren H. S., Cameron P. U., Zhang M. et al. (2003) The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and its overexpression enhances CTL potency. J. Immunol. 170: 805-815
128. Young J. L., Sukhova G. K., Foster D., Kisiel W., Libby P. and Schonbeck U. (2000) The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J. Exp. Med 191: 1535-1544
129. Buzza M. S., Hirst C. E., Bird C. H., Hosking P., McKendrick J. and Bird P. I. (2001) The granzyme b inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell. Immunol. 210: 21-29
130. Bladergroen B. A., Strik M. C., Bovenschen N., van Berkum O., Scheffer G. L., Meijer C. J. et al. (2001) The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166: 3218-3225
131. Kanamori H., Krieg S., Mao C., Di Pippo V. A., Wang S., Zajchowski D. A. et al. (2000) Proteinase inhibitor 9, an inhibitor of granzyme B-mediated apoptosis, is a primary estrogen-inducible gene in human liver cells. J. Biol. Chem. 275: 5867-5873
132. Kannan-Thulasiraman P. and Shapiro D. J. (2002) Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J. Biol. Chem. 277: 41230-41239
133. Hoffmann J. A. and Reichhart J. M. (2002) Drosophila innate immunity: an evolutionary perspective. Nat. Immunol. 3: 121-126
134. De Gregorio E., Han S. J., Lee W. J., Baek M. J., Osaki T., Kawabata S. et al. (2002) An immune-responsive serpin regulates the melanization cascade in Drosophila. Dev. Cell. 3: 581-592
135. Annand R. R., Dahlen J. R., Sprecher C. A., De Dreu P., Foster D. C., Mankovich J. A. et al. (1999) Caspase-1 (interleukin-1 beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem. J. 342 Pt 3: 655-665
136. ten Berge R. L., Meijer C. J., Dukers D. F., Kummer J. A., Bladergroen B. A., Vos W. et al. (2002) Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 99: 4540-4546
137. Bladergroen B. A., Meijer C. J., ten Berge R. L., Hack C. E., Muris J. J., Dukers D. F. et al. (2002) Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 99: 232-237
138. Riewald M. and Schleef R. R. (1995) Molecular cloning of bomapin (protease inhibitor 10), a novel human serpin that is expressed specifically in the bone marrow. J. Biol. Chem. 270: 26754-26757
139. Riewald M., Chuang T., Neubauer A., Riess H. and Schleef R. R. (1998) Expression of bomapin, a novel human serpin, in normal/malignant hematopoiesis and in the monocytic cell lines THP-1 and AML-193. Blood 91: 1256-1262
140. Schleef R. R. and Chuang T. L. (2000) Protease inhibitor 10 inhibits tumor necrosis factor alpha-induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes. J. Biol. Chem. 275: 26385-26389
141. Abts H. F., Welss T., Mirmohammadsadegh A., Kohrer K., Michel G. and Ruzicka T. (1999) Cloning and characterization of hurpin (protease inhibitor 13): a new skin-specific, UV-repressible serine proteinase inhibitor of the ovalbumin serpin family. J. Mol. Biol. 293: 29-39
142. Spring P., Nakashima T., Frederick M., Henderson Y. and Clayman G. (1999) Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. Biochem. Biophys. Res. Commun. 264: 299-304
143. Jayakumar A., Kang Y., Frederick M. J., Pak S. C., Henderson Y., Holton P. R. et al. (2003) Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch. Biochem. Biophys. 409: 367-374
144. Welss T., Sun J., Irving J. A., Blum R., Smith A. I., Whisstock J. C. et al. (2003) Hurpin is a selective inhibitor of lysosomal cathepsin L and protects keratinocytes from ultraviolet-induced apoptosis. Biochemistry 42: 7381-7389
145. Kaiserman D., Knaggs S., Scarff K. L., Gillard A., Mirza G., Cadman M. et al. (2002) Comparison of human chromosome 6p25 with mouse chromosome 13 reveals a greatly expanded ov-serpin gene repertoire in the mouse. Genomics 79: 349-362
146. Forsyth S., Horvath A. and Coughlin P. (2003) A review and comparison of the murine alpha(1)-antitrypsin and alpha(1)-antichymotrypsin multigene clusters with the human clade A serpins. Genomics 81: 336-345
147. Bird C. H., Blink E. J., Hirst C. E., Buzza M. S., Steele P. M., Sun J. et al. (2001) Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor crm1. Mol. Cell. Biol. 21: 5396-5407.
148. Chuang T. L. and Schleef R. R. (1999) Identification of a nuclear targeting domain in the insertion between helices C and D in protease inhibitor-10. J. Biol. Chem. 274: 11194-11198
149. Grigoryev S. A., Bednar J. and Woodcock C. L. (1999) MENT, a heterochromatin protein that mediates higher order chromatin folding, is a new serpin family member. J. Biol. Chem. 274: 5626-5636
150. Irving J. A., Shushanov S. S., Pike R. N., Popova E. Y., Bromme D., Coetzer T. H. et al. (2002) Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J. Biol. Chem. 277: 13192-13201
151. Tabe L., Krieg P., Strachan R., Jackson D., Wallis E. and Colman A. (1984) Segregation of mutant ovalbumins and ovalbumin-globin fusion proteins in Xenopus oocytes. Identification of an ovalbumin signal sequence. J. Mol. Biol. 180: 645-666
152. Palmiter R. D., Gagnon J. and Walsh K. A. (1978) Ovalbumin: a secreted protein without a transient hydrophobic leader sequence. Proc. Natl. Acad. Sci. USA 75: 94-98
153. Belin D. (1993) Biology and facultative secretion of plasminogen activator inhibitor-2. Thromb. Haemost. 70: 144-147
154. Numa F., Takeda O., Nakata M., Nawata S., Tsunaga N., Hirabayashi K. et al. (1996) Tumor necrosis factor-alpha stimulates the production of squamous cell carcinoma antigen in normal squamous cells. Tumour Biol. 17: 97-101
155. Ritchie H. and Booth N. A. (1998) Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-golgi-independent pathway. Exp. Cell. Res. 242: 439-450
156. Scott F. L., Coughlin P. B., Bird C., Cerruti L., Hayman J. A. and Bird P. (1996) Proteinase inhibitor 6 cannot be secreted, which suggests it is a new type of cellular serpin. J. Biol. Chem. 271: 1605-1612
157. Kato H., Nagaya T. and Torigoe T. (1984) Heterogeneity of a tumor antigen TA-4 of squamous cell carcinoma in relation to its appearance in the circulation. GANN 75: 433-435
158. Tsuyama S., Hashimoto K., Nakamura K., Tamura H., Sasaki K. and Kato H. (1991) Different behaviors in the production and release of SCC antigen in squamous-cell carcinoma. Tumour Biol. 12: 28-34
159. von Heijne G., Liljestrom P., Mikus P., Andersson H. and Ny T. (1991) The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J. Biol. Chem. 266: 15240-15243
160. Mimuro J. and Loskutoff D. J. (1989) Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. J. Biol. Chem. 264: 936-939
161. Panyutich A. V., Hiemstra P. S., van Watering S. and Ganz T. (1995) Human neutrophil defensin and serpins form complexes and inactivate each other. Am. J. Respir. Cell. Mol. Biol. 12: 351-357
162. Uemura Y., Pak S. C., Luke C., Cataltepe S., Tsu C., Schick C. et al. (2000) Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int. J. Cancer 89: 368-377
163. Morris E. C., Dafforn T. R., Forsyth S. L., Missen M. A., Horvath A. J., Hampson L. et al. (2003) Murine serpin 2A is a redox-sensitive intracellular protein. Biochem J. 371: 165-173
164. Silverman G. A., Askew D. J., Irving J. A., Luke C. J., Kaiserman D., Bird P. I. et al. (2003) Serpins: Evolution, Nature Publishing Group, London
165. Sun J., Whisstock J. C., Harriott P., Walker B., Novak A., Thompson P. E. et al. (2001) Importance of the P4′ residue in human granzyme B inhibitors and substrates revealed by scanning mutagenesis of the proteinase inhibitor 9 reactive center loop. J. Biol. Chem. 276: 15177-15184
166. Al-Khunaizi M., Luke C. J., Askew Y. S., Pak S. C., Askew D. J., Cataltepe S. et al. (2002) The serpin SQN-5 is a dual mechanistic-class inhibitor of serine and cysteine proteinases. Biochemistry 41: 3189-3199